Compare Credo Technology Group Holding Ltd (CRDO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Credo Technology Group Holding Ltd trades at $225.7 (market cap $44.04B), while State Street SPDR S&P Biotech ETF trades at $156.09. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals.
| CRDO | XBI | |
|---|---|---|
Market Cap | $44.04B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $302.52 | $164.28 |
52-Week Low | $87.81 | $85.16 |
Enterprise Value | $42.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $236.88, down 8.11% over the past 24 hours, with technical indicators showing neutral momentum near key support at $231. The company demonstrates exceptional fundamental strength with 35.37% net income margin and 34.41% ROE, though valuation metrics appear elevated with a P/E of 94.1. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.16 surpassing the $1.02 forecast.
The outlook remains positive with analyst consensus at $273.33 target (15.4% upside) and 87% buy ratings. Key risks include high valuation multiples and dependence on AI infrastructure demand growth. The company's strong cash flow generation and triple-digit revenue growth projections for 2026 support continued upside potential despite near-term volatility.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
